DySIS Medical Appoints New Chairman

DySISmedical, the company behind the world's first digital mapping colposcope, has appointed Martin Hunt to its Board of Directors as Chairman.

Hunt has more than 25 years experience in the medical technology business, including sales and marketing positions in the fields of pharmaceuticals, wound closure and ophthalmic surgery with American Cyanamid, ConvaTec and Bristol-Myers Squibb.

Martin Hunt was appointed CEO of TSL plc in 1999 and under his leadership the company was successfully admitted to AIM – the London Stock Exchange’s international market for smaller growing companies. Following continued growth TSL was subsequently sold to Covidien.Since the sale of TSL, Martin has taken on a portfolio of Board and advisory roles in the life sciences sector including Programme Director NIHR i4i, Deputy Chairman of MDY plc and Deputy Chairman of Trophos SA.

Speaking of his appointment, Martin Hunt said: "DySISmedical has a unique technology which is making significant contributions to women's healthcare. Cervical cancer is an entirely preventable disease if detected in its earliest stages and treated appropriately. The advantages that DySIS offers clinicians in disease screening are well proven in published clinical trials and I'm therefore delighted to be working with the company."

Alastair Atkinson, DySISmedical CEO, said: "I'm delighted that Martin is joining our Board and will be bringing his extensive experience of international growth to DySISmedical as we continue to expand."

For more information about DySIS, including clinical evidence, or to book an appointment to discuss further please visit www.dysismedical.com.

Notes for editors:

In addition to being Chairman of DySISmedical Ltd, Martin Hunt is a board member of the National Institute for Health Research (NIHR), Deputy Chairman of MDY Healthcare plc (a strategic investing company), Vice President and advisor of Trophos SA (a clinical stage pharmaceutical company), a Venture Partner with H20 (a private equity house) and Programme Director of the National Institute for Health Research’s ‘Invention for Innovation’ programme (i4i).

Cervical cancer is the second most common cancer in women and the World Health Organisation estimates that there are over 500,000 new cases each year resulting in 250,000 deaths. In the developed world, where screening programmes are used, some 30 million women will receive an abnormal smear test result and be called for a colposcopy examination. The DySIS (Dynamic Spectral Imaging System) is used to perform this examination according to well-established procedures. The DySIS employs advanced photonics and computer assistance to quantify and map the aceto-whitening process – providing clinicians with reliable information to assist in the identification of pre-cancerous lesions.

DySISmedical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications.

ENDS.